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Abstract
Background: Iodine deficiency disorders (IDD) represent a 
global health threat to individuals and societies. IDD pre-
vention programmes have been introduced in many parts 
of the world. However, challenges remain, particularly in Eu-
rope due to fragmentation and diversity of approaches that 
are not harmonized. Objectives: This review is dedicated to 
the public-health impact of IDD prevention programmes. It 
sums up experiences collected by the EUthyroid consortium 
so far and provides information on stakeholders that should 
be involved in actions directed to improve the impact of IDD 
prevention. Methods: A joint European database for com-
bining registry-based outcome and monitoring data as well 
as tools for harmonizing study methods were established. 
Methods for analyzing thyroglobulin from a dried blood 
spot are available for assessing the iodine status in the gen-
eral population and at-risk groups. Mother-child cohorts are 
used for in-depth analysis of the potential impact of mild-
to-moderate iodine deficiency on the neurocognitive devel-
opment of the offspring. A decision-analytic model has 
been developed to evaluate the long-term effectiveness 
and cost effectiveness of IDD prevention programmes. Re-
sults: EUthyroid has produced tools and infrastructure to 
improve the quality of IDD monitoring and follows a dis-
semination strategy targeting policymakers and the gener-
al public. There are tight connections to major stakeholders 
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in the field of IDD monitoring and prevention. Conclusions: 
EUthyroid has taken steps towards achieving a euthyroid 
Europe. Our challenge is to inspire a greater sense of urgen-
cy in both policymakers and the wider public to address this 
remediable deficit caused by IDD.
© 2018 European Thyroid Association 
Published by S. Karger AG, Basel
Background 
Iodine deficiency disorders (IDD) represent a global 
health threat to individuals and societies. According to 
the World Health Organization, iodine deficiency is the 
single most important, preventable cause of brain dam-
age worldwide [1]. Iodine deficiency during pregnancy 
and breast feeding is widespread in Europe and adversely 
affects the development of the child [1]. Adults living in 
iodine-deficient regions carry a high risk of goiter, thy-
roid nodules and hyperthyroidism. Subclinical hyperthy-
roidism, as a common and frequently undiagnosed IDD 
[2, 3], is tightly associated with an increased risk of mor-
tality and coronary heart disease [4].
Thus, effects of iodine deficiency impose tremen-
dous, preventable resource costs on the health-care sys-
tems of affected regions. Iodine deficiency can easily be 
prevented by iodine fortification and was pioneered in 
Switzerland in 1922 [5]. Since then, IDD prevention 
programmes have been introduced in many parts of the 
world by fortifying table salt, staple foods and livestock 
feed. However, challenges remain, particularly in Eu-
rope, due to fragmentation and diversity of approaches. 
To the extent that regular programmes exist at all, iodine 
fortification may be based on the voluntary or the man-
datory principle, different carriers are used (e.g., potas-
sium iodide or iodate), different foods may be iodized 
(e.g., bread, dairy products) and target concentrations 
for salt iodization vary. Similarly, monitoring and evalu-
ation of IDD prevention programmes across nations is 
either absent or not systematic. Moreover, the cost-ef-
fectiveness of IDD prevention has rarely been explored, 
probably because it is widely assumed that due to the low 
cost of salt fortification, such programmes provide value 
for money.
This review is dedicated to the public-health impact of 
IDD prevention programmes and is intended to provide 
background information of the Krakow Declaration of 
Iodine, which is published in this issue of the European 
Thyroid Journal [6]. The review sums up experiences col-
lected by the EUthyroid consortium so far and provides 
information on stakeholders that should be involved in 
actions directed to improve IDD prevention.
This heterogeneity in national regulations poses challenges to 
large European food companies and has resulted in a decreasing 
proportion of iodine-fortified food.
EUthyroid: To Improve the Level of Scientific Evidence 
Objectives
In the era of fake news and conspiracy theories, sound 
scientific evidence remains a pivotal precondition for po-
litical decisions. EUthyroid, a pan-European consortium, 
was formed in close cooperation with the Iodine Global 
Network (IGN). EUthyroid is working towards the fol-
lowing specific objectives with the aim of ending IDD in 
Europe and beyond:
1. Collation of national registry data to analyze asso-
ciations between iodine status and disease outcomes;
2. Harmonization of national iodine studies to pro-
duce a valid European map of iodine status;
3. Capacity building for harmonized IDD prevention 
and monitoring, including assessment of thyroglobulin 
(Tg) as an innovative and cost-effective biomarker of io-
dine status in individuals and populations;
4. Evaluation of Tg in pregnant women as a biomarker 
for iodine status and the effect of maternal iodine status 
on neurocognitive function in children; 
5. Proof of long-term cost-effectiveness of IDD pre-
vention and monitoring programmes in European re-
gions with mild-to-moderate iodine deficiency;
6. Support for harmonized IDD prevention and mon-
itoring in European countries through dissemination of 
EUthyroid outcomes. 
Results 
Registry-Based Outcomes
While a large number of studies that monitor the io-
dine status in populations exist, there is almost no out-
come research that provides evidence of the effectiveness 
of IDD prevention programmes in terms of declining 
prevalence and incidence of IDDs and related therapies 
[7]. A joint European database for combining national/
regional registry-based outcome data related to iodine 
status has been established.
Experience: The extreme heterogeneity of registry data 
across European countries is a great challenge for outcome 
research. In many countries, access to registry data is hin-
dered by so-called data protection. Outcome data in a single 
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country is sometimes collected by different institutions such 
as health insurance companies and various associations of 
health-care providers. In federally structured countries, na-
tionwide data is sometimes unavailable. Across  European 
countries, there are no general recommendations, guide-
lines, or standards on how to collect specific data, and this 
trend hampers data comparability between countries. How-
ever, registry data can be very useful for comparisons across, 
for example, the Scandinavian countries where nationwide 
registry data is collected for administrative purpose and 
where the health care systems are similar.
Conclusion: Policymakers have to be made aware of 
their public health-related responsibilities and the fact 
that the evaluation of IDD prevention programmes in 
their countries is obligatory. European and national au-
thorities have to ensure the accessibility of data for health 
research. Access procedures, database structure and reg-
ulatory frameworks for use of health-care data should be 
harmonized within and across European countries. 
Harmonization of National IDD Monitoring Studies 
EUthyroid has improved the harmonization of nation-
al and regional IDD monitoring studies by standardizing 
them, collecting national and regional IDD data to estab-
lish a joint European database with information on the 
prevalence of thyroid-related biomarkers. Online tools 
and infrastructures enabling a continuous harmonization 
of data collection and monitoring have been established. 
One of the key features is the gold-standard EUthyroid 
laboratory. It has detected large inter-laboratory differ-
ences in measurement of urinary iodine concentrations 
between national laboratories, clearly emphasizing the 
need for more work to improve the validity of iodine 
analysis for thyroid epidemiology [8] (Fig. 1, 2).
The same challenges were noted in the collection of in-
terview and ultrasound data. Standardized questionnaires 
to assess the socioeconomic status in different languages 
are available (http://euthyroid.eu/questionnaires-page/) 
as well as training and certification tools for laboratory 
staff and sonographers (http://euthyroid.eu/training/).
The joint database of harmonized regional and nation-
al IDD monitoring studies has been the basis for the map-
ping the iodine status and thyroid disorders (Fig. 3). The 
EUthyroid map is available at http://euthyroid.eu/map/. 
Experience: The quality of monitoring studies is hetero-
geneous. Common limitations include non-representative 
study populations and inadequate standardization of inter-
views, ultrasound examinations and laboratory procedures, 
resulting in low validity of some study results and hampered 
comparability between studies from different countries.
Conclusion: Policymakers and government officials 
must be made aware that they are responsible for the 
monitoring of IDD prevention programmes in their 
countries. Researchers do not have to ask for monitoring 
studies to be carried out; politicians should ask research-
ers to carry out appropriate monitoring that achieves the 
best possible population representativeness and validity 
of study results. On the European (and global) level, in-
tensive efforts are required to establish and extend tools 
and infrastructure for standardization and quality assur-
ance in monitoring studies. 
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Fig. 1. Comparison of urinary iodine concentration (UIC) levels 
(µg/L) between one national laboratory and the EUthyroid labora-
tory. As illustrated by Bland and Altman plot, the national labora-
tory measures on average 49.46 µg/L higher values than the gold-
standard laboratory in the same urine samples. The differences are 
even higher in the upper measurement range.
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Fig. 2. Example of urinary iodine excretion (UIE) levels before (left 
boxplot) and after correction for the gold-standard measurements 
(right boxplot). The status of the investigated population changed 
from iodine sufficiency to moderate iodine deficiency. UIC, uri-
nary iodine concentration.
Völzke et al.Eur Thyroid J 2018;7:193–200196
DOI: 10.1159/000490347
Thyroglobulin
Tg is a thyroid-specific protein and a storage and syn-
thesis site for thyroid hormones. During iodine deficien-
cy or excess, the increase in the thyroid activity leads to 
an increase in the blood Tg concentration [9]. Tg can be 
measured in dried blood spots (DBS), which can simplify 
collection, storage and transport in field studies. DBS-Tg 
could also be a sensitive functional biomarker to assess 
iodine status in pregnant women and women of repro-
ductive age [4]. However, there is less data on Tg concen-
trations in women of varying iodine intake in Europe. 
Experience: Although collection and analysis of DBS 
Tg from women across Europe is ongoing, preliminary 
data suggests that day-to-day variation in DBS-Tg is 
modest and that DBS Tg may be a good functional indica-
tor of iodine status in European pregnant women [10].
Conclusion: Although DBS Tg is a promising biomark-
er of iodine status in pregnant women, there may be ad-
ditional environmental and genetic factors that influence 
Tg concentrations, and these need to be further investi-
gated before Tg can be recommended for routine use in 
monitoring the iodine status.
Maternal Iodine Status during Pregnancy and 
Neuropsychological Development of the Offspring 
Although the negative consequences of severe iodine 
deficiency for offspring neurocognitive development are 
beyond doubt [11], the effects of mild-to-moderate io-
dine deficiency on cognition are relatively unexplored. 
EUthyroid overcomes this knowledge gap by providing 
new data on maternal iodine status in relation to neuro-
development, by performing additional iodine measure-
ments and harmonizing and integrating data from 3 large 
European cohorts of different iodine status. 
Experience: More evidence is needed that even mild-
to-moderate iodine deficiency during pregnancy affects 
offspring neurocognitive development, but given the 
long-term follow-up needed to obtain valid results, the 
potential study base is sparse. The collaboration between 
3 major European prospective mother-child cohorts in 
the EUthyroid consortium of differing iodine status (i.e., 
ALSPAC [12], moderately iodine deficient; INMA [13], 
mildly iodine deficient; Generation R [14], iodine suffi-
cient) allows an individual participant-based meta-anal-
ysis to relate maternal iodine status in pregnancy to off-
spring neurocognitive function. Primary neurocognitive 
outcome will be child IQ (5–10 years of age) and second-
ary outcomes will include neuropsychological diseases. 
Conclusion: When there is more evidence from obser-
vational studies that mild-to-moderate iodine deficiency 
during pregnancy affects the neurocognitive function of 
the offspring, and which women are particularly at risk, 
subsequent clinical trials are needed to demonstrate ben-
eficial effects of iodine supplementation. 
Health Economics, Health Technology Assessment 
and Health Policy 
Due to a variety of IDD prevention programmes and 
associated complex and uncertain consequences, it is es-
sential for decision makers systematically to evaluate ben-
efits, potential harms and cost-effectiveness of prevention 
strategies. EUthyroid has developed a decision-analytic 
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Fig. 3. Region of the EUthyroid map illus-
trating the iodine status of populations 
measured as urinary iodine concentration. 
The map not only provides information on 
countries as a whole, but also on regions 
and communities, where iodine monitor-
ing studies have been performed.
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model [15] to evaluate the long-term effectiveness and cost 
effectiveness of IDD prevention programmes. All relevant 
health conditions and events potentially caused by iodine 
deficiency or affected by related prevention programmes 
are included. The natural history of IDDs and related dis-
orders as well as the parameters for effectiveness, quality of 
life and costs are derived from clinical trials, observational 
studies and expert surveys. Since long-term effectiveness 
data is rarely available in the field, the model can also be 
used to explore the effect of uncertainty regarding the du-
ration of the effect of a prevention program that may sug-
gest the need for further empirical research. 
Experience: There is surprisingly low evidence of cost 
effectiveness of IDD prevention based on existing pro-
grammes. 
Conclusion: More evidence on cost-effectiveness of 
IDD prevention may convince health authorities to pay 
more attention on the optimization of prevention pro-
grammes. Cost-effectiveness analyses must take into ac-
count the need for information campaigns, monitoring 
studies and evaluation analyses.
Monitoring Iodine Status and Evaluation of  
IDD Prevention 
Monitoring studies serve to inform the practicalities of 
iodine fortification. Changes in the political environment, 
food production or dietary habits may lead to unforesee-
able changes in the iodine status of populations [16]. There 
are no specific recommendations on time intervals be-
tween monitoring studies but countries should consider 
regular 5-year intervals. Given the low prevalence of thy-
roid diseases and related treatments in young people, mon-
itoring studies should preferably be done in school-chil-
dren. Studies should be representative of the investigated 
region and, owing to the high intra-individual variation in 
iodine intake, should comprise at least 100 participants per 
study region [17]. The calculation of iodine intake from 
food-frequency questionnaires may be complicated by 
highly variable iodine content in foods; this may especially 
be the case in regions with IDD prevention programmes 
based on the voluntary principle [18]. The measurement of 
iodine from urinary samples is a well-established method 
[7], but should be done in certified laboratories. Alterna-
tively or additionally, measurements of thyroglobulin in 
DBS can be used to define iodine status [19]. Complemen-
tary monitoring studies should be conducted in risk groups 
that are especially prone to IDD, including, for example, 
pregnant women and women of reproductive age [20].
The primary goal of prevention measures is to reduce the burden 
of disorders related to iodine deficiency in societies. Monitoring 
cannot substitute studies for the effectiveness of IDD prevention.
The use of health-registry data is an efficient way to as-
sess indicators of effectiveness of IDD prevention [21]. Op-
timal IDD prevention is reached when there is a balance 
between a low incidence of IDD, including hypothyroidism 
in newborns and goiter, thyroid nodules and hyperthyroid-
ism in adults, on the one hand, and autoimmune thyroid 
disease and hypothyroidism on the other hand. Over the 
course of IDD prevention, registry data should demon-
strate a reduction in thyroid-related therapies over time [7].
Stakeholder Institutions and Organizations
EU and DG Sante 
EUthyroid recognizes that the EU is unable to provide 
general legislation for all states concerning recommenda-
tions for optimal iodine nutrition for the population. 
However, it is to be hoped that the EU will take note of the 
findings of EUthyroid and use these to underpin public 
health policy advice to individual member states. In the 
long run, the EU should take responsibility for health-pol-
icy recommendations to national member states to enable 
the harmonization of prevention programmes for all. 
Implications for Public Health Officers and Public 
Health Departments 
Due to the very high prevalence of IDD in affected 
populations, prevention can be easily introduced and can 
save cost when the programme is effective. Mandatory 
programmes are easier to steer than programmes based 
on the voluntary principle. Responsible authorities must 
supply budgets for accompanying information cam-
paigns to improve the awareness of the general public; 
this is of particular importance for voluntary programmes.
Likewise, budgets must be made available for subse-
quent monitoring and continuous registry studies to con-
trol the effectiveness of IDD prevention. For the latter, 
health registries have to be made accessible to researchers. 
It is the obligation of health authorities rather than the 
responsibility of scientists to ensure the sustainable con-
trol of IDD prevention. 
Implications for the European Food Safety Agency
The European Food Safety Agency (EFSA) Panel 
on Dietetic Products, Nutrition and Allergies published 
in a Scientific Opinion on Dietary Reference Values 
Völzke et al.Eur Thyroid J 2018;7:193–200198
DOI: 10.1159/000490347
(DRVs) for iodine produced DRVs for iodine, which 
were provided in terms of Adequate Intake in 2014 [22]. 
The updated data provided by EUthyroid should enable 
the revision of these DRVs, where necessary, to re-
flect the current iodine status in EU countries. For in-
stance, the proposed adequate intake for lactating wom-
en of 200 µg/day assumes the existence of substantial 
iodine stores in conditions of adequate iodine status be-
fore pregnancy. However, EUthyroid is likely to re-
veal the fact that many European women of childbearing 
age do not enter pregnancy with substantial iodine 
stores; this is certainly the case in the United Kingdom 
[23–25].
European Thyroid Association Public  
Health Committee 
The European Thyroid Association (ETA) has been 
providing policy advice relating to all aspects of thyroid 
disease for 50 years. During the funding period of EUthy-
roid, regular reports have been given to the committee. 
The ETA will consider the final report of EUthyroid and 
publicize its recommendations. It will also consider how 
best to advise on future policy for iodine nutrition in Eu-
rope.
World Iodine Association
World Iodine Association (WIA) is an internation-
al  non-profit organization established to support and 
represent iodine producers, processors, formulators, 
distributors and end users in relevant industry and of-
ficial government bodies around the world. Parallel in-
terests between WIA and EUthyroid include the advo-
cacy towards international institutions and key stake-
holders of the optimum use of iodine in human nutrition, 
the transfer of scientific evidence on IDD prevention 
to  the general public and to policymakers and to en-
sure the high quality of iodine production and food pro-
cessing.
There is close contact between EUthyroid and the 
WIA. At the IGN satellite meeting of the ETA 2017 con-
gress, which was co-organized by EUthyroid, the WIA 
reported on current activities and ambitions of WIA. 
Likewise, EUthyroid members gave presentations at the 
2007 WIA congress on Iodine and Health and are mem-
bers of the WIA scientific advisory board. 
European Salt Producer’s Association 
To implement the introduction of iodised salt into Eu-
ropean countries that do not currently consume it, Euro-
pean salt producer’s association (EU Salt) will be of great 
assistance. EU Salt has extensive salt company networks 
that can facilitate the production and regulation of io-
dised salt for public consumption. Contacts between 
members of EUthyroid and EU Salt have been strength-
ened and their help is much appreciated.
Iodine Global Network 
The IGN has strongly supported the EUthyroid ini-
tiative. It recognizes that while optimal iodine nutri-
tion  is being achieved in many countries in Asia, the 
Americas and Australasia (all hitherto iodine deficient) 
through the introduction of iodized salt, this in general 
has not occurred in Europe. It is hoped that the results 
of EUthyroid will encourage urgent advocacy for har-
monization of iodine supply in the whole continent of 
Europe.
Advocacy Issues: National Policy Officers 
Populations face changing environmental conditions 
and nutritional behavior. Promoting restricted salt con-
sumption and the increasing use of milk-free dairy prod-
ucts are only 2 examples that may worsen the iodine sta-
tus of populations emphasizing the need for regular mon-
itoring studies. Since the responsibility for health issues 
in the EU lies with the single member states, national au-
thorities are responsible for state-of-the-art monitoring. 
An EU regulation statement would support efforts to co-
ordinate collaboration, would support evidence-based 
studies and establish quality control of ongoing pro-
grammes.
Advocacy is required to promote the following crucial objec-
tives:
 − To educate all partners involved in iodine-deficiency control/
monitoring to facilitate and improve their collaboration with 
national health authorities,
 − To increase the awareness of national policymakers of the im-
portance of monitoring iodine supply to obviate easily prevent-
able adverse health and educational consequences,
 − To mobilize national policymakers to take responsibility to 
raise awareness among communities of the importance of ad-
equate iodine consumption and the necessity for IDD preven-
tion, 
 − To inform national health authorities of the need to maintain 
their supervision of the salt and food industries with respect to 
iodine supply,
 − To bring current changes in environmental and dietary behav-
ior specific to each country and to the whole European popula-
tion to the attention of national policymakers,
 − To cooperate with consumer associations to advocate con-
sumption of the required amount of iodine according to dietary 
patterns; attitudes of consumers also affect legislation efforts,
 − To inform the general public by appropriate campaigns, prefer-
ably funded by public agencies,
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 − To actively involve industry, including the salt and food indus-
tries, and agriculture to control and ultimately prevent iodine 
deficiency, 
 − To establish an iodine working group in each country to pre-
pare a detailed and scheduled activity plan,
 − To ensure that actions aiming to improve iodine intake in pop-
ulations are implemented and that they are in line with current 
dietary recommendations and salt reduction initiatives. Em-
phasis should be placed on replacing non-iodized salt with io-
dized in the majority of food products.
Publicity, Press and Media 
Evidence-based policymaking reflects the belief that 
social goals are best served when policy decisions are 
based on rigorous and comprehensive scientific evidence. 
Modern democracies are under intense influence from 
pressure groups that present scientific evidence in a piece-
meal, manipulated, or cherry-picked manner. The term 
policy-based evidence making has been coined to reflect 
a process in which evidence is selected to conform to cer-
tain ideological positions and thus selected facts are used 
to support conceived wisdom. In such a scenario, selected 
scientific evidence is misappropriated to lend legitimacy 
to decisions and signal the intention of the decision mak-
ers to settle political debate [26].
The EU has set up a “Scientific Advice Mechanism,” 
which supports decision making of the College of 
 European Commissioners upon request with indepen-
dent scientific advice. However, a path for scientific input 
to enter policy making in areas where no requests are for-
mulated remains less obvious, not only on the European 
but also on the national level. Many theories of policy-
making remain stuck in an outdated deficiency model, 
which presumes that when the scientific community 
reaches consensus on a topic, the evidence will somehow 
enter decision-making processes. In particular, it be-
comes much more obvious that participation in policy 
debates is not driven by a desire to be technically accurate, 
but rather by a need for political success [27]. It is not 
even clear on which remit scientists should participate in 
decision-making processes and what resources they 
would draw on to compete in the political arena with 
commercial and political interests. Therefore, today 
many scientists are confused about how to reach policy 
makers with their scientific evidence. 
Under the specific remit to influence decisions, EU-
thyroid allocated a considerable amount of time and re-
sources towards achieving improved IDD monitoring 
and prevention in Europe. Therefore, EUthyroid engaged 
not only an interested public and the wider scientific 
community, but also policy makers at the national and 
European level. 
Under the guidance of the IGN, an experienced team was es-
tablished to implement a dissemination plan, which rested on the 
6 pillars:
1. Producing scientific evidence on iodine monitoring and pre-
vention programmes.
2. Generating high-quality content to engage various stake-
holders.
3. Exploiting an extensive network of regional and national 
contacts.
EUthyroid partners have been proactively distributing 
facts about IDD through the project website and social 
media. Press releases have been published, national stake-
holders contacted and meetings attended. The EUthyroid 
twitter account has reached more than 180 followers. 
While this number is modest and are far from reaching 
any significant proportion of the general audience, it 
compares well to other dissemination activities of re-
search projects, which are frequently in the low 2-digit 
numbers. To all partners of EUthyroid, the fact that the 
public remains oblivious to the problem of iodine defi-
ciency remains a great challenge. If a general audience, 
supported by media attention, recognizes a public-health 
concern as a pressing need, policymakers are more likely 
to be engaged and more likely to recommend urgent ac-
tion. 
Conclusions 
EUthyroid has made steps forward to achieve an opti-
mally iodine sufficient Europe. Our challenge is to inspire 
a greater sense of urgency in both policymakers and the 
wider public to address this remediable deficit that is in-
creasing the burden of IDD to societies and individuals and 
adversely affecting the mental abilities of our children.  
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